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The goal of this study was to investigate the bioavailability, efficacy, and safety 
of inhaled remifentanil, inhaled remimazolam, and combinations of both drugs in mouse, 
rat, and pig models. Anesthesiology could benefit from efficacious, noninvasively 
delivered, short acting, and thereby easily titratable analgesic/sedative agents. 
Remifentanil and remimazolam are potentially advantageous due to their esterase-based 
metabolism and rapid elimination profiles, particularly to high-risk populations such as 
obese, elderly, and pediatric populations. Dosing via spontaneous respiration can 
inherently and safely control the duration and level of sedation and analgesia via patient 
minute ventilation. There is no inhaled opioid or benzodiazepine currently available for 
clinical use as an anesthetic agent.  
It was our hypothesis that remifentanil and remimazolam delivered by inhalation 
would be rapidly absorbed, pharmacologically active, rapidly cleared, and noninjurious to 
rodent airways and lungs. We also hypothesized that the pharmacokinetics of inhaled 
remifentanil in pigs would exhibit similar rapid onset and recovery.   
Inhaled remifentanil in rats induced profound analgesia with rapid recovery. 
Inhaled remimazolam in mice produced sedation, while inhaled remimazolam in rats did 
not produce sedation at the maximum dose able to be achieved in aerosols. Remimazolam 




Pulmonary mechanics and histology showed no irritation or injury by either drug or the 
combination. Pharmacokinetic analysis of both drugs in rodents were consistent with the 
pharmacological effects and a study of inhaled remifentanil in pigs demonstrated rapid 
absorption and clearance of the drug consistent with those reported for intravenous 
dosing in humans and animals. We have shown that remifentanil and remimazolam, 
administered alone or in combination, can be a clinically relevant method of anesthesia. 
These fundamental experiments and results are critical for the future development of 
formulations for inhalation delivery of these drugs for clinical use. These inhaled drugs 
could eventually revolutionize the ease and practicality of administering inhaled 
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Current potent inhaled anesthetics used for general anesthesia include isoflurane, 
sevoflurane, and desflurane.  Although the exact mechanism of action of these agents is 
unknown, it is thought that inhalational agents interact with numerous ion channels 
present in the central and peripheral nervous system, such as activating gamma-
aminobutyric acid (GABA) through chloride channel conductance.1 These agents can 
cause varying degrees of risk to patients, including hemodynamic instability, nausea, and 
airway irritation.  In addition, they are greenhouse gases, which are not currently 
regulated. There is also a risk of recall, or lack of amnesia, at lower doses, which can 
cause patients to have memories of painful or traumatic experiences.  Inhaled anesthetics 
are desirable due to the ability to administer these anesthetics through a mask or secured 
airway.  Dose adjustments can easily be made with each breath.  There is currently no 
inhaled benzodiazepine or opioid available today, and development of these drugs for 
delivery via inhalation would be of clear clinical value to anesthesia practice to use in 
conjunction with, or possibly even in place of, the halogenated inhaled agents used today.   
Remifentanil, an injectable, ultra-short acting µ-opioid receptor agonist, is FDA 
approved for use in human patients. Remimazolam, an analogue of midazolam, is a 
GABAA allosteric modulator and is a new benzodiazepine currently in Stage III clinical 





introducing a metabolically labile and pharmacologically essential ester moiety that is 
readily susceptible to hydrolysis, and thus clearance, by esterases.  This unique structural 
feature imparts remimazolam and remifentanil with more specific desirable properties, 
such as shorter duration of action and more easily titratable effects during anesthesia. 
These properties could improve ease of administration, titration, and recovery from 
anesthesia in medically complicated patients, such as obese patients and extremes in age. 
Clearance of remifentanil and remimazolam is body weight and ventilation independent, 
thereby ideal for obese patients.  These drugs follow first order kinetics. However, if 
esterases were to become saturated, they would follow zero-order kinetics, but this is 
unlikely at recommended dosing. Most other anesthetic drugs are lipophilic and 
accumulate in fat, as manifested by prolonged half-lives and larger volume of distribution 
due to redistribution to lipid compartments. This results in delayed arousal from 
anesthesia and lingering anesthetic effects.  Today’s surgical population is becoming 
increasingly diverse, with complex medical issues. This population would benefit from 
the distinct clinical advantages of inhaled ester-based drugs, which include: easier 
titratability; IV-independent administration; facilitated sedation, analgesia, and amnesia 
for pediatric populations; body weight-independent clearance; a safety profile in which 
respiratory depression will limit uptake of the drug while metabolism continues, thereby 
preventing overdose; and drug reversibility via naloxone (remifentanil) or flumazenil 
(remimazolam). There are no currently available inhaled opioids or benzodiazepines for 
anesthetic use. As these drugs have only been studied via the traditional intravenous 
route, very little is known regarding the feasibility, efficacy, and pharmacokinetics when 





Today’s surgical population is complex, and high-risk patient procedures are on 
the rise, frequently requiring case-specific adjustments to anesthesia regimens. High-risk 
patients include obese patients with variable comorbidities, the young, and the elderly. 
This demographic change is due to both an increase in surgery rates worldwide, and 
advances in medicine, allowing medically complicated patients to live longer.  The 
development of new, potent, highly titratable, short-acting anesthetic agents with greater 
safety margins across a diverse patient population could substantially improve the quality 
of care and reduce risks of surgical/anesthesia-related complications in high-risk patients; 
inhaled remimazolam and remifentanil represent such anesthetic agents. 
 
Obesity-Associated Anesthesia Challenges 
   
The World Health Organization has declared obesity a global epidemic, which has 
increasingly affected the management of anesthesia.2  It is noted that 35.7% of the US 
population is obese.3 Consequently, obesity-related diseases such as obstructive sleep 
apnea, hypertension, hyperlipidemia, type II diabetes, cardiovascular disease, orthopedic 
joint related derangements, and certain types of cancer are also on the rise.4-6  These 
aforementioned diseases predispose patients to the need for surgery. In fact, outpatient 
surgery visits have increased over 300% between 1996-2006, with an estimated 57.1 
million outpatient surgeries taking place in 2006.7  Morbidly obese patients are at much 
higher risk for complications during surgery, including death.6  
Obese patients also frequently present with obesity-related airway and pulmonary 
changes that include anatomically difficult upper airway access and Pickwickian 





of both obstructive sleep apnea (OSA) and restrictive type breathing.  Because many 
more general inhaled anesthesia cases will be performed on obese patients in the near 
future, more airway complications during induction and at the end of surgery are also 
expected to occur.9 Additionally, once safely exiting the operative theatre, postoperative 
patients with obesity and obesity-related complications require careful monitoring in the 
postanesthesia care unit (PACU).  Particularly, patients with OSA may require a longer 
stay as compared with non-OSA patients undergoing similar procedures.10  This is due to 
their propensity to develop airway obstruction or central respiratory depression,10 which 
is in part related to redistribution of lipophilic anesthetic agents back to the central 
compartment, in addition to pain medication requirements in the postoperative period. 
The unique pharmacological properties of remimazolam and remifentanil provide 
anesthetic choices that have rapid onset, short duration of action, and body-weight 
independent clearance, which could provide an increased safety margin during vulnerable 
operative times, such as induction, emergence, and recovery from anesthesia.  
 
Age-Associated Anesthesia Challenges 
 
Pediatric inpatient and outpatient surgery is also on the rise.  Children less than 
eight years of age do not routinely have an intravenous (IV) line placed before surgery, 
thus necessitating anesthesia induction by intramuscular (IM) injection of ketamine and a 
benzodiazepine, such as midazolam, or mask inhalation with sevoflurane. However, these 
approaches are less than ideal. IM ketamine and midazolam can greatly prolong recovery 
from anesthesia, especially after short anesthetics. Further, ketamine/midazolam also has 





induction with sevoflurane can be complicated by breath holding and laryngospasm. An 
additional limitation of current practice is that oral benzodiazepines are also often given 
before surgery to facilitate amnesia.  Benzodiazepine delivery can be complicated by 
problems with swallowing, the desire for an empty stomach before surgery, limited 
absorption, and slow onset after oral ingestion.  Also, patients pretreated with oral 
benzodiazepines have delayed recovery, with an increased incidence of emergence 
agitation after receiving an inhaled anesthetic.12 Midazolam has a half-life of 1.5-2.5 
hours, which is significantly longer than the duration of most surgeries. The half-life of 
midazolam is increased in young children, and increased half-life paired with the active 
metabolite alpha-1-hydroxymidazolam can result in emergence agitation that can last up 
to 2 days in rare instances, and can be associated with prolonged postanesthesia care 
compared to nonagitated children.13 Additionally, trauma to the child or to the site of 
surgery can occur in agitated patients.12  The use of a rapid onset, rapid clearance, 
respirable anesthetic, such as remimazolam and/or remifentanil, could substantially 
decrease issues with placing IV lines and ingestion of medications, as well as possibly 
lower the risk of emergence delirium in children due to rapid elimination. Inhaled 
remifentanil could provide rapid analgesia with noninvasive delivery, an option that is 
not currently available. Specifically for remimazolam, pediatric patients may also benefit 
from amnesia without the long-term negative effects associated with currently available 
anesthetics.14   
The elderly are yet another rapidly growing surgical population with unique 
anesthetic considerations.  The population over age 85 is projected to increase 350% 





135%.15  These patients require special anesthetic considerations as health conditions 
shift from acute to chronic conditions.15 Many of these patients take multiple 
medications, increasing the possibility of drug interactions.  The presence of sleep apnea 
also increases with age.10  Geriatric patients more frequently display reduced rates of 
drug metabolism, thereby also increasing risk for emergence delirium and postoperative 
cognitive dysfunction after anesthesia with currently available inhaled anesthetics.16 
Elderly patients would benefit from an inhaled anesthetic exhibiting liver and kidney 
independent metabolism, predictable and rapid drug clearance, decreased risk for 
cognitive impairment postoperatively,16 and the ability to fully reverse if necessary;  no 
such anesthetic is currently available.  
 
Inhaled Ester-Based Anesthetics-A New Paradigm for Anesthesia 
  
One of the major benefits of ester-based compounds is the lack of uncertainty 
involved with renal and hepatic metabolism, which is affected by patient health status and 
extremes in age. Specifically, due to comorbidities frequently occurring in today’s 
patients, variations in renal and hepatic status are not always unequivocally known before 
surgery.  A patient’s health status is often an educated guess based on a patient’s medical 
history and physical appearance.  Esterase-mediated metabolism and clearance of inhaled 
medications largely removes this metabolic uncertainty, and ester-based medications 
work through well-defined mechanisms. Ester-based medications are metabolized at a 
constant rate by plasma esterases, independent of body weight,17 renal, and hepatic 
function.  Ester-based medications also remove uncertainty associated with drug 





by hepatic cytochrome P450 3A4, which is susceptible to functional modulation by many 
drugs and dietary agents, is polymorphic, and is differentially expressed in patients, thus 
increasing the possibility for a patient to display variations in efficacy and safety.18 The 
ester-based benzodiazepine remimazolam, and the ester-based opioid remifentanil present 
much lower risk for these types of adverse events, due to esterase metabolism in the 
blood, thereby circumventing metabolic differences seen with drugs, such as midazolam, 
that require liver metabolism.  These would also be the only inhaled anesthetics that will 
be fully reversible by IV injection, thereby adding a layer of safety unavailable with any 
other inhaled anesthetics.     
With inhaled remimazolam and remifentanil, dosage, in a nonconventional way, 
can be dynamically adjusted by the patient’s depth and rate of ventilation. Patients 
experiencing pain or distress will reflexively hyperventilate, thereby allowing for 
delivery of proportionally more inhaled anesthetic.  Alternatively, overdose can be 
attenuated, as a highly sedated patient will hypoventilate, thereby causing less medication 
to be delivered.  Standard inhaled anesthetics require active pulmonary elimination before 
a patient will arouse.  This not only is physiologically harder in sicker patients, but also 
translates to a much longer emergence time for patients who are at increased risks for 
complications. Costly complications due to residual effects of anesthesia could be 
reduced by the use of rapid acting and rapidly metabolized medications.  Additionally, 
rapid plasma elimination of remimazolam and remifentanil facilitates titration as well as 
rapid patient arousal after surgery.  These characteristics of inhaled remimazolam and 






There are currently no ester-based inhaled benzodiazepine or opioid available on 
the market today. Characteristics of an ideal anesthetic include ample potency, reliable 
amnesia, ability to titrate in high concentration oxygen, reliable smooth induction and 
maintenance of general anesthesia, odorless, safe for all ages, lack of injury to vital 
tissues, lack of propensity to cause seizures, lack of respiratory irritation or circulatory 
stimulation, little or no effect on the environment, and low acquisition cost.20 
Traditionally, lack of metabolism has been viewed as a desirable trait, as current inhaled 
anesthetics are exhaled unchanged.  We theorize that complete metabolism would be 
more ideal, facilitating complete recovery independent of respiratory pattern.  This would 
be a paradigm shift, suggesting a novel trait for ideal anesthetic agents. There is currently 
no ideal anesthetic agent available for use. Inhaled remimazolam and remifentanil have 
the characteristics of ideal anesthetics and could revolutionize the way anesthesia is 
performed in the future.  We hypothesized that remifentanil and remimazolam (CNS 
7056) would produce rapid onset of analgesia and sedation, followed by rapid recovery, 
while being noninjurious and nonirritating to lung tissues of rodents. These drugs would 
then be able to provide an alternative method of dosing with clear clinical advantages. 
Innovative and clinically beneficial components of this research are listed in Figure 1.1.  
An overview of each chapter is listed in Figure 1.2 
 
Figure 1.1: Innovation and clinically beneficial components of this project. 
 1)  Development of new inhaled analgesic and amnestic anesthesia agents that would increase safety 
for high-risk populations such as the obese, young, and elderly. 
 2)  Dynamic respiratory dosing allowing ease of titration and an increased safety margin. 
 3)  Respiration-independent clearance, allowing for rapid emergence from anesthesia. 
 4)  Development of the only inhaled anesthetics that are not greenhouse gases.21  






Figure 1.2: Overview 
 
Overview of Chapter 2: Inhaled Remifentanil in Rodents 
 
The second chapter of this dissertation consists of a published manuscript about 
inhaled remifentanil in rodents.  Although it goes into detail on the experiments and 
findings, what is missing is a description of some of the hurdles that were necessary to 
overcome in order to perform these experiments.  As this drug delivered by inhalation 
had never been investigated in any model, animal or human, development of a delivery 
chamber, a method to reliably test analgesia, and an animal model would need to be 
developed or decided upon.  First, a whole body exposure chamber was chosen, as the 
animal would need to be unanesthetized to test analgesic response. A whole body 
inhalation exposure system was constructed essentially as described by Schroder et al. 
(2009)22 with some modifications, which are described in Chapter 2. A micromist 
nebulizer was chosen because it was something that has been used extensively in clinical 
practice, was readily available, and it was capable of producing an aerosol small enough 
to facilitate deep lung deposition (2.7 micrometers per the package insert).  Previous 
research has found that particle size is key to deep lung deposition allowing for maximal 
absorption of the inhaled drug, with particle size <5 micrometers showing the best 
Chapter 1: Introduction and overview of subsequent chapters 
Chapter 2: Inhaled Remifentanil in Rodents 
Chapter 3: Inhaled Remimazolam in Rodents 
Chapter 4: Pharmacokinetics of Inhaled Remifentanil in a Porcine Model 
Chapter 5: Determination of Remifentanil and Remimazolam in Blood by Liquid Chromatography-Mass 
Spectrometry 
 





absorption.23 Rats were chosen because of extensive available research on pain 
measurements in rats, as well as cost and ease of use. Various ways of producing pain 
were attempted, such as tail rolling, paw pinching, electrical stimulation, and three 
different researchers monitored the rats for evidence of sedation, such as decreased 
movement, ataxia, laying down, and dropping their heads.  Although the rats showed 
obvious signs of analgesia and sedation, it quickly became evident that whether or not a 
rat demonstrated pain when its paw was pinched was not easy to quantify. Therefore, Dr. 
Alan Light from the Department of Anesthesiology was consulted, who is an expert in 
rodent pain models.  Dr. Light recommended the use of a tail flick meter to objectively 
measure analgesic response to painful stimuli.  This meter electronically measures time to 
tail movement due to localized heat sensitivity, allowing for quantitative measurement of 
the analgesic effect in rats. He provided this machine for our use in these studies.  
Next, a concentration of remifentanil to deliver by aerosol needed to be chosen.  It 
was evident that a whole-body exposure chamber would require much more drug than 
intravenous or even intratracheal delivery. Therefore, starting at a very high 
concentration was decided, knowing there were many obstacles to overcome. It was 
unknown how much of the drug would be metabolized by pulmonary esterases before 
reaching the brain, or if exhaustion of pulmonary esterases would result in zero-order 
kinetics resulting in prolonged recovery.  Also, rainout into the exposure chamber was a 
possibility. To limit rainout in the rodent’s airway, 0.9% saline was used as a carrier 
solution, since remifentanil is readily soluble in saline and saline is an isotonic solution 
when compared to airway fluids.  The first concentration of 2000 mcg/mL was delivered 





profound analgesia when measured by tail flick meter.  This provided initial proof of 
concept that inhaled remifentanil was bioavailable. Based on these results, the 
experiments outlined in Chapter 2 were performed.  
 
Overview of Chapter 3: Inhaled Remimazolam and 
 
Remifentanil in Rodents  
 
After many months of discussion with Paion Pharmaceuticals in Aachen, 
Germany, a shipment containing a vial of powdered remimazolam was received.  Unlike 
remifentanil, which was readily water soluble, remimazolam created quite an obstacle 
when attempting to make a solution due to hydrophobicity.  The lofty original goal was to 
aerosolize a liquid solution of 250-350 mg/mL, which was quickly recognized to be quite 
unrealistic.  After several failed attempts, it was found that remimazolam could be 
solubilized at a concentration of 25 mg/mL when dissolved first in 100% dimethyl 
sulfoxide (DMSO), then diluted to 10% DMSO with 0.9% saline; this was a reasonable 
vehicle composition for aerosol generation and delivery.  The chamber described above 
was subsequently modified to deliver inhaled remimazolam.  It was found that the forced 
air nebulizer was not compatible with remimazolam.  The saline would aerosolize, 
leaving a thick slurry of DMSO and remimazolam in the nebulizer.  Contact was made 
with Aerogen Ltd. (Galway, Ireland).  Aerogen’s patented nebulizers use a palladium 
mesh that is perforated with 1,000 precision formed holes that vibrate at 128,000 times 
per second resulting in vaporization of the drug solution.   After discussion with their 
research team, Aerogen generously donated an Aerogen lab vaporizer for this research.  





remimazolam, Paion had used loss of righting reflex, the pinna reflex (ear flick in 
response to gentle touch of the auditory meatus), and the haffner reflex (response to paw 
pinch) to measure sedation in rats.  With this information, modifications were made to the 
exposure chamber to allow for such testing during inhalation drug exposure.  After 
spending most of the day at a local home improvement store, a toilet flange and a rubber 
glove were used to modify the chamber. These were secured to the top of the chamber, 
allowing a gloved hand to enter the exposure chamber to perform reflex testing.  
However, after exposing rats to inhaled remimazolam in this chamber, it was discovered 
that our drug concentration was not nearly high enough to cause measureable sedation in 
rats.   
 It was decided to change to a mouse model, as a 20 gram mouse was 1/10 the 
body weight of the 200+ gram rats, and the drug solution of 25 mg/mL was 1/10 of our 
desired drug solution of 250 mg/mL. It was found that after exposure to aersolized 
remimazolam, mice retained the pinna, haffner, and righting reflex, but they did appear 
sedated. The mice did not move for minutes or even hours, depending on the exposure/ 
dose, which was significantly different than control mice.  We adapted the study to look 
at time to movement outside a 4-inch square perimeter as a measure of sedation following 
exposure to inhaled remimazolam for 10 minutes. The results of this pilot study are 
shown in Figure 1.3. 
With evidence of the ability to elicit profound sedation in mice, ways to relate 







Figure 1.3: Sedative response to increasing concentrations of inhaled 
remimazolam (orange bars) following exposure for 10 minutes as 
measured by time to movement outside set perimeter.   
*=statistically different than pretest baseline or vehicle control P=0.01 
**=statistically different than pretest baseline or vehicle control P<0.0006 




pursued. It was decided to give various concentrations of the combination of drugs to rats 
and evaluate for potentiated analgesic response, as opioids and benzodiazepines are  
frequently given in combination in operating rooms to complement each other.  This  
 




























































































Overview of Chapter 4: Inhaled Remifentanil in a Porcine Model 
 
Following favorable results when testing inhaled remifentanil in a rodent model, 
subsequent testing in a large animal model using a custom delivery system that was 
reasonably comparable to what could be used in humans was indicated. Through 
collaboration with the Department of Anesthesiology, a study on intubated Duroc pigs 
was initiated.  A sensitive and selective liquid chromatography mass spectroscopy 
method was required for the pharmacokinetic analysis.  Also, an appropriate dose and 
delivery method needed to be determined. Dr. Chris Stockmann (Dept. of Pediatrics) was 
consulted regarding the optimal sampling regime he had developed for inhaled 
remifentanil in rats.  It was decided that this same pharmacokinetic model would work 
well for the pharmacokinetic study in pigs.  A dose of 100 mcg/kg inhaled remifentanil 
was chosen. This relatively high dose was chosen to be sure that the drug could be 
detected, as we had concerns about variable pulmonary absorption.  The first pig was 
scheduled.  Following intramuscular sedation, two peripheral intravenous lines were 
placed in the ears, as well as an arterial line in the femoral artery.  The pig was intubated 
and sedated by intravenous infusion to prevent interference with pulmonary absorption. 
Following administration of aerosolized remifentanil, samples were drawn for 
pharmacokinetics (PK) analysis. These samples were assayed using a validated liquid-
chromatography-tandem mass spectrometry (LC-MS-MS) method and showed detectable 
levels of inhaled remifentanil. Details of this study and the development and validation of 








Overview of Chapter 5: Determination of Remifentanil and Remimazolam 
 
in Blood by Liquid Chromatography-Mass Spectrometry 
 
 Chapter 5 outlines the development and validation of an LC-MS-MS method for 
the analysis of the combination of remifentanil and remimazolam in blood.  
 
Overview of Chapter 6: Conclusion  
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INHALED REMIFENTANIL AND 
 





Remimazolam is an ester-based short acting benzodiazepine in clinical trials. This 
study explored the feasibility of delivering remimazolam as an adjunct to remifentanil via 
inhalation. Rats were exposed to remimazolam and remifentanil aerosol alone and in 
combination. Analgesia was quantified by using a tail flick meter and pulmonary injury 
was assessed using mechanics measurements.  Exposure of rats to inhaled remimazolam 
alone failed to produce sedation or analgesia following a 5-minute exposure.  Rats 
exposed to both remimazolam and remifentanil exhibited a significant increase in 
analgesia as compared to the same doses of either agent alone. Remimazolam delivered 
alone or in combination with remifentanil was nonirritating to the respiratory tract of 
mice. Inhaled Remimazolam can significantly potentiate the analgesic effect of inhaled 
remifentanil when concurrently delivered.  
Introduction 
 
Remimazolam is an ester-based benzodiazepine in phase III clinical trials. Much 
like the opioid remifentanil, remimazolam is rapidly cleared by plasma esterases to a 





positive allosteric modulator on the GABAA receptor. However, remimazolam differs 
from other benzodiazepines based on its ester-based pharmacophore, which allows for 
rapid metabolism independent of hepatic or renal function.1-3  
Inhaled midazolam has been investigated for seizure protection in mice,4 but the 
efficacy of inhaled remimazolam is unknown.  Previous research on inhaled remifentanil 
has shown rapid onset of analgesia and rapid recovery, while being noninjurious and 
nonirritating in rodents.5 Benzodiazepines are frequently used to augment opioid effect 
during anesthesia. The objective of this study was to demonstrate that inhaled 
remimazolam in conjunction with inhaled remifentanil would potentiate analgesia versus 




 All described studies were approved by the Institutional Animal Use and Care 
Committee (IACUC) at the University of Utah. Mice were housed 5/cage and rats were 
housed 2/cage in an AAALAC-approved vivariam maintained at 22-26°C with relative 
humidity 40-50% under 12/12-h light/dark cycles. Water and standard lab chow was 
provided ad libitum. Time to tail flick study was performed using male Sprague-Dawley 
rats weighing between 200-300g. Pulmonary mechanics measurements were performed 
using 8-week-old male C57Bl/6 mice weighing 19-25 grams and a Flexivent FX-1 








Drugs and Reagents 
 Remimazolam was graciously provided by PAION pharmaceuticals (Aachen, 
Germany). Remifentanil was purchased from Mylan Inc. (Canonsburg, PA, USA). 
Ketamine/xylaxine and methacholine were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific 
(Pittsburgh, PA, USA). Vecuronium was purchased from Sun Pharmaceuticals (Mumbai, 
Maharashtra, India). 
Inhalation Chamber 
 The whole body inhalation chamber used was as previously described in Bevans et 
al.,5 which was adapted from a small animal inhalation chamber described by Schroderer 
et al. (RF 18). Essentially, a 6.5-quart Hefty® bin was fitted with a low-volume 
Micromist nebulizer (Hudson RCI, Morrisville, NC) and an Aerogen Lab ultrasonic 
nebulizer (Aerogen Ltd., Galway, Ireland). The Micromist nebulizer produced a particle 
size of approximately 2.7 micrometers through a forced air nebulizer and was used to 
nebulize remifentanil.  The aerogen nebulizer produces 2.5-4.0 micrometer volume mean 
diameter aerosolized particles through a vibrating palladium mesh which vibrates 
128,000 times per second and was used to nebulize remimazolam.  
 
Analgesic Testing 
Analgesia was assessed as described previously.5 Breifly, analgesia was measured 
using a IITC Tail Flick Analgesia Meter (model 336G, IITC Life Science, Woodland 
Hills, CA). A 4 x 6 mm heat source generated a tail stimulus, and tail movement away 





were tested 2 cm from the tip using 50% light intensity and a preprogrammed cut-off 
time of 20 seconds to prevent tissue damage or suface burn injury to the rat. 
Time to Tail Flick Study 
This study of 25 rats was performed in addition to the dose response study of 53 
rats already performed using inhaled remifentanil.5  Time to tail flick in drug-exposed 
groups was compared to time to tail flick in pretest baseline and inhaled saline control 
groups.  For this study, remimazolam was tested at 10 and 25 mg/mL, and in combination 
with remifentanil 100 mcg/mL or 250 mcg/mL. 
Pulmonary Mechanics 
30 mice (n=5/group) were used to assess pulmonary function following acute 
aerosolized remimazolam exposure and acute and repeated exposure to combined inhaled 
remimazolam and remifentnail using a Flexi-Vent FX-1 small animal ventilator (Scireq, 
Montreal, Qc, Canada). Specifically measured were changes in lung resistance (Rrs), 
airway resistance (Rn), tissue resistance (G), lung compliance (Crs), lung elastance (Ers) 
and tissue elastance (H).  These were determined using a constant-phase model which has 
been extensively used to assess lung mechanics in mice.6,7  Methods were also as 
previously described in Bevans et al.5  
For acute remimazolam exposure, control mice were exposed to vehicle (10% 
DMSO/ 90% normal saline) for five treatments followed by a methacholine challenge of 
25 mg/mL. Treatment mice were exposed to one dose of vehicle followed by four 
treatments of increasing concentrations of remimazolam (5, 10, 15, 20 mg/mL), followed 





exposed to vehicle control, followed by four treatments of 200 mcg/mL remifentanil 
combined with 20 mg/mL remimazolam, followed by a methacholine challenge (25 
mg/mL).  These mice were compared to mice exposed 5 times to vehicle followed by 
methacholine.  For repeated sub-acute exposure, mice were exposed to a combination of 
250 mcg/mL remifentanil and 20 mg/mL remimazolam every other day for 3 treatments 
via the whole body exposure chamber.  Forty-eight hours following the third exposure, 
pulmonary mechanics were measured as above.  
Statistical Analysis 
Statistical analysis was performed as in Bevans et al.5 The experiments featured 
in this study were powered to achieve 80% power with one-way ANOVA and two-
sample t-tests. The Shapiro-Wilk test was used to assess the normality of the data and/or 
the residuals prior to performing any statistical comparisons. Data are expressed as 
medians (interquartile range [IQR]) and comparisons between groups at a single point in 
time were performed using the t test or the nonparametric Mann-Whitney U test, as 
appropriate.  
The time to tail flick test was performed using a student’s t test. The acute 
pulmonary mechanics experiments were performed using a one-way ANOVA. For all 
comparisons, P<0.001 was considered to be statistically significant. All statistical 
comparisons were two-sided. R 3.1.1 (R Foundation for Statistical Computing, Vienna, 
Austria) and Graphpad Prism (La Jolla, CA, USA) were used to perform the power 








Time to Tail Flick 
Inhalation of remimazolam alone failed to produce analgesia.  Concentrations >25 
mg/mL could not be tested due to lack of solubility in a reasonable vehicle. When 
remimazolam (10 or 25 mg/mL) was administered in combination with 250 mcg/mL 
remifentanil there was a significant difference in time to tail flick (P<0.0001), 
comparable to analgesia achieved using 1000 mcg/mL remifentanil alone (P<0.0001).  




Figure 3.1. Analgesic response to increasing concentrations of inhaled remifentanil 
and/or remimazolam for 5 minutes as measured by time to tail flick.  Maximum test 
duration 20 seconds. 
***Significant difference from pretest baseline (P<0.0001) and inhaled saline (P=0.0002) 
****Indicates significant difference from baseline and saline control (P<00001) 











































































































































































Acute inhalation delivery of remimazolam up to 20 mg/mL did not alter the 
pulmonary mechanics of mice (Figure 3.2). Likewise, mice acutely (Figure 3.3) or sub-
acutely (Figure 3.4) exposed to a combination of remifentanil and remimazolam showed 
no alterations to pulmonary mechanics, except when comparing the methacholine 
challenge for airway resistance, where sub-acutely exposed mice showed diminished 
changes in lung resistance compared to vehicle exposed mice (P<0.0007).  These data 
show that remimazolam alone or in combination with remifentanil does not cause lung 
irritation, bronchospasm, or other adverse pulmonary events.  As previously reported,5 
the decrease in lung resistance is attributable to remifentanil. 
Discussion 
 
 This study advances previous research on inhaled remifentanil,5 which concluded 
that inhaled remifentanil was rapidly absorbed, pharmacologically active, rapidly cleared, 
and noninjurious.  These additional experiments show that remimazolam, when 
administered in conjunction with remifentanil, has a synergistic affect on analgesia while 
also sharing the desired pharmacokinetic, pharmacodynamic, and safety profile of ester-
based, short acting agents. Although it would be ideal to test higher concentrations of 
inhaled remimazolam alone, this was not possible due to limitations in solubility. As 
such, the clinical utility of remimazolam as a single inhaled sedative is low compared to 
remifentanil, but its use as a potentiating agent for inhaled remifentanil is a realistic 






   
   
   
   
   





Figure.3.2. Pulmonary mechanic measurements after exposure to increasing  















































































Dose response of lung resistance of C57Bl/6 mice acutely exposed 
to increasing concentrations of inhaled remimazolam (mg/mL RM) 
as compared to inhaled vehicle (10% DMSO/ 90% saline) exposure, 
followed by 25 mg/mL methacholine (MeCH) challenge. n=5
Ve 1 1 2 M
Dose response of airway resistance (Rn) of C57Bl/6 mice acutely 
exposed to increasing concentrations of inhaled remimazolam (mg/
mL RM) as compared to inhaled vehicle (10% DMSO/ 90% saline) 











































































Dose response of lung compliance of C57Bl/6 mice acutely exposed to 
increasing concentrations of inhaled remimazolam (mg/mL RM) as 
compared to inhaled vehicle (10% DMSO/ 90% saline) exposure, 
followed by 25 mg/mL methacholine (MeCH) challenge. n=5
Dose response of tissue damping or resistance (G) of C57Bl/6 mice 
acutely exposed to increasing concentrations of inhaled remimazolam 
(mg/mL RM) as compared to inhaled vehicle (10% DMSO/ 90% saline) 














































































Dose response of lung elastance of C57Bl/6 mice acutely 
exposed to increasing concentrations of inhaled 
remimazolam (mg/mL RM) as compared to inhaled vehicle 
(10% DMSO/ 90% saline) exposure, followed by 25 mg/mL 
methacholine (MeCH) challenge. n=5
V
Dose response of tissue elastance of C57Bl/6 mice acutely exposed to 
increasing concentrations of inhaled remimazolam (mg/mL RM) as 
compared to inhaled vehicle (10% DMSO/ 90% saline) exposure, followed 








   
   
   
   
   




Figure 3.3. Pulmonary mechanics measurements after acute exposure to a combination of 







































































































Acute remifentanil + 
remimazolam
25
Lung resistance of C57Bl/6 mice repeatedly exposed to 200 mcg/mL remifentanil (RF) 
combined with 20 mg/mL remimazolam (RM) by inhalation as compared to inhaled vehicle 
(10% DMSO/ 90% saline) exposure, followed by methacholine (MeCH) challenge. n=5
Lung compliance (Crs) of C57Bl/6 mice repeatedly exposed to 200 mcg/mL remifentanil (RF) 
combined with 20 mg/mL remimazolam (RM) by inhalation as compared to inhaled vehicle 



















































Acute remifentanil + 
remimazolam



















































Airway resistance (Rn) of C57Bl/6 mice repeatedly exposed to 200 mcg/mL remifentanil (RF) 
combined with 20 mg/mL remimazolam (RM) by inhalation as compared to inhaled vehicle 
(10% DMSO/ 90% saline) exposure, followed by methacholine (MeCH) challenge. n=5
2
Figure 4A: Acute exposure. Lung elastance (Ers) of C57Bl/6 mice repeatedly exposed to 200 
mcg/mL remifentanil (RF) combined with 20 mg/mL remimazolam (RM) by inhalation as 


















































Acute remifentanil + 
remimazolam
Tissue damping or resistance (G) of C57Bl/6 mice repeatedly exposed to 200 mcg/mL 
remifentanil (RF) combined with 20 mg/mL remimazolam (RM) by inhalation as compared to 

















































Acute remifentanil + 
remimazolam
Tissue elastance (H) of C57Bl/6 mice repeatedly exposed to 200 mcg/mL remifentanil (RF) 
combined with 20 mg/mL remimazolam (RM) by inhalation as compared to inhaled vehicle 





   
   
   












Figure 3.4. Pulmonary mechanics measurements following exposure to 
sub-acute combination of inhaled remimazolam and remifentanil 












































































































































































































































































































Subacute RF + RM
Subacute vehicle
25
Lung resistance (Rrs) of C57Bl/6 mice after repeated pulmonary exposure to 200 mcg/mL 
remifentanil (RF) and 20 mg/mL remimazolam (RM)  with repeat prior exposure to inhaled RF 
and RM as compared to mice with repeated exposure to inhaled vehicle, followed by 
methacholine challenge. n=5, ***=P<0.0007
2
Lung compliance (Crs) of C57Bl/6 mice after repeated pulmonary exposure to 200 mcg/mL 
remifentanil (RF) and 20 mg/mL remimazolam (RM)  with repeat prior exposure to inhaled RF and 
RM as compared to mice with repeated exposure to inhaled vehicle, followed by methacholine 
challenge. n=5
2
Figure 4B: Subacute exposure. Lung elastance (Ers) of C57Bl/6 mice after repeated pulmonary 
exposure to 200 mcg/mL remifentanil (RF) and 20 mg/mL remimazolam (RM)  with repeat prior 
exposure to inhaled RF and RM as compared to mice with repeated exposure to inhaled vehicle, 
followed by methacholine challenge. n=5
Airway resistance (Rn) of C57Bl/6 mice after repeated pulmonary exposure to 200 mcg/mL 
remifentanil (RF) and 20 mg/mL remimazolam (RM)  with repeat prior exposure to inhaled RF and RM 
as compared to mice with repeated exposure to inhaled vehicle, followed by methacholine challenge. 
n=5
Tissue damping or resistance (G) of C57Bl/6 mice after repeated pulmonary exposure to 200 mcg/mL 
remifentanil (RF) and 20 mg/mL remimazolam (RM)  with repeat prior exposure to inhaled RF and RM 
as compared to mice with repeated exposure to inhaled vehicle, followed by methacholine challenge. 
n=5 
25
Tissue elastance (H) of C57Bl/6 mice after repeated pulmonary exposure to 200 mcg/mL 
remifentanil (RF) and 20 mg/mL remimazolam (RM)  with repeat prior exposure to inhaled RF and 
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PHARMACOKINETICS OF INHALED REMINFENTANIL 
 





Remifentanil is an ester-based μ-opioid receptor agonist. Little is known about the 
pharmacokinetics of inhaled remifentanil.  The object of this study was to study the 
population pharmacokinetics of inhaled remifentanil in an intubated porcine model. A 
sensitive and specific liquid chromatography-tandem mass spectrometry (LC-MS-MS) 
method for the determination of remifentanil was developed and validated. Arterial blood 
samples of 1 mL were collected at various time points from an anesthetized intubated pig 
following administration of 100 µg/kg inhaled remifentanil. Population pharmacokinetic 
modeling was performed using a nonparametric adaptive grid (NPAG) using a one-
compartment model (NONMEM, ICON plc, Dublin, Ireland).  The population 
pharmacokinetic model using a single compartment model show a plasma clearance rate 
(CL) of 0.41 ± 0.18 with the volume of the central compartment being 0.03 ± 0.02. The 
predicted model adequately reflects the observed model (R2=0.884) 
Introduction 
Remifentanil is a potent μ-opioid receptor agonist FDA approved for intravenous 





it susceptible to ester hydrolysis by blood and tissue esterases allowing for an ultra-short 
duration of action.  This rapid metabolism is relatively independent of infusion duration, 
and/or hepatic/renal function.1,2  The carboxylic acid metabolite (GI-90291) and the N-
dealkylated metabolite (GI-94219) have less than 1% of the potency of the parent 
compound and are thereby considered essentially inactive1 (Figure 4.1).  
The pharmacokinetic properties of inhaled remifentanil have not been previously 
described in humans or large animals.  The aim of this study was to characterize the 
pharmacokinetics of inhaled remifentanil in anesthetized, intubated pigs, using frequent 
blood sampling and computer-assisted pharmacokinetic modeling techniques. The intent 
 
 
Figure 4.1. Chemical structure of remifentanil and major de-esterified 
metabolite (GI-90291) and minor P450 metabolite (GI-94219) 






was to further pharmacokinetic data available on inhaled remifentanil, as earlier research 
has shown inhaled remifentanil to have rapid onset and metabolism with marked efficacy 
in a rodent model.3  To increase translatability to humans, this study utilized a porcine 
model, as pigs have breathing volumes and rates similar to humans due to a 
cardiopulmonary system that is similar to humans.  Also, previous pharmacokinetic (PK) 
data on inhaled remifentanil in rodents were limited by blood volume preventing serial 
blood draws.3 The larger blood volume of pigs allows for multiple serial blood draws 
from the same animal to assay circulating remifentanil concentrations.   
 Our hypothesis was that remifentanil would be rapidly absorbed and rapidly 
cleared following pulmonary administration to intubated pigs. We expect that inhaled 
remifentanil will have similar pharmacokinetic properties to intravenous remifentanil, 
although it is expected that an increased intrapulmonary dose will be required to produce 
comparable blood levels due to dead space in the anesthesia circuit, and loss of drug to 
rainout and exhalation compared to the amount of lung reaching distal airways.  A 
nebulizer producing a small particle size of 2.5-4 microns was used to help facilitate deep 
lung deposition to maximize absorption. This research will develop a sensitive and 
selective method for the detection of remifentanil in blood using LC-MS-MS. This 




The Institutional Animal Use and Care Committee (IACUC) at the University of 





Solutions (Great Bend, KS, USA). Pigs weighing 26-32kg were housed in pairs in a fully 
staffed and AAALAC-approved vivarium. The vivarium was maintained at 20-26°C with 
a relative humidity of 40-50% under 12/12-h light/dark cycles. Pigs were provided water 
and standard pig chow; food was deprived for 8 hours preprocedure.  
Drug and Reagents 
Remifentanil was purchased from Mylan Inc (Canonsburg, PA, USA). 
Meperidine (IS) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Formic acid, 
acetonitrile (ACN) and methanol were purchased from Fisher Scientific (Fair Lawn, NJ, 
USA). Ethyl Acetate was purchased from VWR International (Radnor, PA, USA). 
Propofol and fentanyl were purchased from Pfizer (NY, NY, USA). Bovine blood was 
purchased from Sierra Medical (Whittier, CA, USA).  
Instrumentation 
LC-MS-MS measurements were performed using a Thermo Finnigan TSQ 
Quantum AM (Thermo Scientific, Waltham, MA, USA).  Separation of remifentanil and 
IS was achieved chromatographically using an Xbridge C8 (50 mm x 2.1 mm) HPLC 
column (Waters, Milford, MA, USA). The column was equilibrated with a flow rate of 
0.25 mL/min with a mobile phase consisting of 10% ACN, 90% aqueous formic acid.  
Upon sample injection, the concentration of ACN was increased to 25% over 5 minutes. 
This held at 25% ACN, 75% formic acid for 0.5 minutes then ACN decreased to 10% for 
the final 5.5 minutes. The autosampler was maintained at room temperature and the 






Calibrator and Quality Control Solution Preparation 
Stock solutions of remifentanil were prepared in saline at a concentration of 1000 
ng/μL. Stock solutions of meperidine (IS) were also prepared at a concentration of 1000 
ng/μL. Intermediate solutions of remifentanil were prepared at concentrations of 100, 10, 
1, 0.1, and 0.01 ng/μL by performing serial dilutions. Intermediate solutions of IS were 
prepared by serial dilution to concentrations of 100, 10, and 2 ng/μL. All stocks and 
intermediate solutions were stored in glass tubes at -20°C for the duration of the study. 
Working solutions were prepared immediately prior to use.  
Calibrator and quality control (QC) solutions were prepared from intermediate 
solutions by aliquoting 1 mL of bovine blood into 13 x 100 mm screw top glass culture 
tubes (Fisher Scientific, Fair Lawn, NJ, USA) fortified with 50 ng/mL IS (25 μL of 2 
ng/μL IS). A total of 12 bovine blood samples were used for calibration curves with a 
final concentration of 0, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25, 50, 75, and 100 ng/mL with a 
total of 50 ng/mL IS added. Liquid-liquid extraction was performed by adding 4 mL of 
ethyl acetate to each sample, vigorously shaking, then vortexing for 10 seconds. Samples 
were then centrifuged in a Beckman GPR centrifuge with a 20.4 cm rotor (GH 3.7) at 
3,500 rpm for 10 minutes. The bottom organic supernatant was transferred into a new 
glass tube, and dried under a constant flow of air.  The dried residue was reconstituted in 
50 μL of 20%ACN/80% H2O.  Reconstituted samples were transferred to the autosampler 
for analysis.  QC samples were prepared in the same manner in the following 






Accuracy and Precision 
Both intra- and interassay accuracy and precision were determined.  The 
percentage of the expected and calculated analyte concentration using the mean (n=5) 
was used to determine the accuracy in a single batch of samples at concentrations of 75, 
50, 10, and 1 ng/mL. Intra-assay precision was expressed as percent relative standard 
deviation (%RSD) and was determined by using the standard deviation of the actual 
measured concentration at each concentration divided by the mean assayed concentration. 
Interassay precision was determined by dividing the standard deviation of the assay 
concentration (75, 50, 10, and 1 ng/mL) by the concentration of the mean concentration 
for three separate batches (n=20 for each).  
Recovery 
Recovery of remifentanil from blood was determined using quality control 
samples at 2.5 and 75 ng/mL (n=5) and compared to unextracted samples. Recovery for 
remifentanil was calculated to be between 76 and 89% 
Stability 
Using quality control samples, the effect of various storage conditions on stability 
were tested. Autosampler stability of samples at 75, 50, 10, and 1 ng/mL (n=5) and stored 
at room temperature in the auto sampler overnight were re-run against freshly prepared 
calibrators and controls. There was no degradation of internal standard under these 
conditions. Concentrations of 75 and 2.5 ng/mL were stored for 1 hour in blood at room 
temperature on the bench top prior to extraction, and were compared to samples 





comparing the mean assayed concentration with the mean concentration of untreated QC 
samples.  
Animal Exposure and PK Sample Collection 
Each pig was sedated by intramuscular injection of a mixture of 4.4 mg/mL 
Telazol® (tiletamine), 2.2 mg/kg xylazine, and 2.2 mg/kg ketamine.  Once adequate 
sedation was achieved, two separate 18g intravenous catheters were placed in the ears. IV 
sedation was maintained with a propofol infusion (4-5 mg/kg/hr) and fentanyl infusion 
(100 mcg/kg/hr). A solution of normal saline was infused at 50 ml/hr. Ventilation was 
maintained with an 8.0 endotracheal tube and volume-control ventilation with 2L flow of 
100% oxygen, tidal volume of 15 ml/kg, and respiratory rate of 12/min. A 20-g arterial 
line was accessed through the femoral artery for purposes of blood sampling and 
continuous blood pressure monitoring. Pigs were also continuously monitored by 
electrocardiograph, blood pressure, and pulse oximetry to assess adequacy of anesthetic 
depth and ensure adequate ventilation. 
Remifentanil was administered through a 2.5-4.0 μm volume median diameter 
Aerogen nebulizer unit (Aerogen Ltd. Galway, Ireland) fitted into the inspiratory arm of 
the breathing circuit (Figure 4.2).  100 μg/kg remifentanil reconstituted in normal saline 
to a final volume to 2.5 mL was administered over approximately 10 minutes. Blood 
samples of 1 mL each were collected at 0, 1, 2.5, 5, 7.5, and 9 minutes during drug 
delivery and at 10, 11, 12.5, 15, 20, 25, 40, 55, 70, and 130 minutes after drug delivery 








Figure 4.2.  Vaporizer set-up in the anesthesia circuit: 
A. Anesthesia circuit  B. Aergoen vaporizer 
C. Endotracheal tube 
 
PK Sample Preparation 
Fresh pig aliquots of 1mL were mixed in Fisherbrand 13 x 100 mm screw top 
glass culture tubes prefilled with 4 mL ethyl acetate fortified with 50 ng/mL IS 
(meperidine), shaken vigorously, and kept on ice. Following collection, samples were 
vortex mixed for 10 seconds, and centrifuged (3,500 rpm for 10 minutes); the organic 
solvent was transferred to a clean tube, and evaporated to dryness.  Samples were stored 
at -70°C until analysis.  To test ex-vivo stability, 1 mL bovine blood was spiked with 75 
and 2.5 ng/mL remifentanil and left at room temperature for 1 hour.   
Results 
Liquid Chromatography-Tandem Mass Spectrometry 
The analysis of remifentanil in blood exhibited a lower limit of quantification 
(LLOQ) of 0.25 ng/mL.  The upper limit of quantification (ULOQ) was 100 ng/mL, 





Remifentanil was readily detectable with a run time of 11 minutes. The predominant 
product ion had a mass to charge ratio of 285 (m/z 377.1→285.0) (Figure 4.3). The plot 
of the ratio of analyte and internal standard peak area versus calibrator concentration was 
nonlinear over the range of 0.25-100 ng/mL.  Calibration curves were fit to a quadratic 
equation, weighted 1/X2, where X was the analyte concentration. Calibration curves 
generated in this manner exhibited a correlation coefficient (r2) that was ≥0.98. The 
accuracy of the assay was ≥90% (n=5).  The intra-assay precision was <8% RSD for all 
analytes at the four quality control concentrations. 
 
 
Figure 4.3. Chromatogram of remifentanil (top left) 
compared to a blank chromatogram (top right) 
and meperidine (bottom) peaks. Remifentanil 
peak is at a concentration of 2.5 ng/mL 
(top left) and 0 ng/mL (top right) and 
meperidine peak is at 50 ng/mL. 
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The interassay precision was <15% RSD and the accuracy of the assay was ≤88% 
for all quality control concentrations (Table 4.1). Recovery of remifentanil from blood 
was between 76-90% (Table 4.2). Samples were stable (71-100% initial target 
concentration) after 24 hours in the autosampler at room temperature (20% ACN/80% 
H20).  Samples left at room temperature on the bench top for 1 hour were also stable at 
76-89% of the nonaged samples (Table 4.3).  
 
 
Table 4.1.  Accuracy and Intra- and Interassay Precision (%RSD) for 
Quality Control Standards Containing Remifentanil 















































Table 4.3.  Stability of Remifentanil in Standards 
Stored under Various Conditions 










90 ± 14 
86 ± 14 
71 ± 16 
100 ± 12 




88 ± 7 





Analysis of Biological Samples 
  Analysis of blood collected from pigs following exposure to inhaled remifentanil 
demonstrates rapid uptake and rapid metabolism following cessation of administration 
(Figure 4.4). Peak concentrations of remifentanil in pig blood ranged from 40-100 
ng/mL. Population pharmacokinetic parameters estimate the volume of distribution (V) to 
be 0.03 ± 0.02 liters (L) with a clearance of 0.41 ± 0.18 L/hr (Table 4.4). Individual 
pharmacokinetic parameters estimate volume of distribution (V) between 0.01 and 0.07 L 
and a clearance between 0.23 and 0.66 L/hr, with an estimated half-life between 0.03 and 





Figure 4.4. LC-MS-MS analysis of concentration of remifentanil in blood following 
timed blood draws during and after inhalation of remifentanil in pigs 










































































Table 4.4. Population Pharmacokinetic Parameter Estimates 
of Inhaled Remifentanil in Pigs 
 Mean SD CV Variance Median 
V 0.03 0.02 70.79 0.00 0.03 
CL 0.41 0.18 44.61 0.03 0.34 
V=plasma volume (L), CL=clearance (L/hr 
 
 
Table 4.5. Individual Pharmacokinetic Parameters 
of Inhaled Remifentanil in Pigs 
 V CL Ke Half-life 
1 0.01 0.23 22.49 0.03 
2 0.07 0.66 9.77 0.07 
3 0.02 0.34 13.37 0.05 
V=plasma volume (L), CL=clearance (L/hr), 




A sensitive and selective method was devfeloped for the detection of remifentanil 
in blood using LC-MS-MS. Using this method, the assayed concentrations for the 
fortified quality control samples were 90-114% of the target concentrations for analytes. 
This method produced very similar values for the quality control samples on separate 
days, exhibiting an interassay precision of <15% RSD. In general, remifentanil was not 
significantly affected by different storage and handling conditions. Level of detection is 
within therapeutic dose range.  
Samples from pigs after exposure to inhaled remifentanil show that remifentanil is 
rapidly absorbed and metabolized. Pharmacokinetic analysis of intravenous remifentanil 
showed a peak effect within 1-3 minutes.2 Inhaled remifentanil shows similar onset of 
action. Observed concentrations were slightly higher overall than predicted 
concentrations for inhaled remifentanil as the model is shifted somewhat to the left 







Figure 4.5. Observed (x-axis) versus predicted (y-axis) population 
pharmacokinetic model for inhaled remifentanil in pigs 
 
 
= 0.884), despite the small sample size (n=3). Future samples will add power to this 
model.  After a total of 10 pigs, the model will be re-evaluated and assessed for accuracy, 
at which point more pigs may be added.   
The pharmacokinetics of intravenous remifentanil shows a half-life of 3 minutes, 
with a 10-minute terminal half-life.1 Our data thus far also show a population half-life of 
3 minutes. Additionally, aerosol exposure in one pig over 27 minutes shows the ability to 
deliver inhaled remifentanil over a longer period of time (Figure 4.6).  This relative 
plateau in remifentanil blood concentration with a longer exposure period is consistent 
with clinical needs for longer anesthetics, while maintaining remifentanil’s rapid 








Figure 4.6: Pharmacokinetics of inhaled remifentanil 
with a 27-minute exposure period 
 
The administered dose of 100 μg/kg is a high dose, in part due to waste associated 
with intrapulmonary delivery through an endotracheal tube.  This translates to greater 
drug waste and increased cost.  Although Aerogen nebulizers average an impressive 35% 
lung deposition,4 total amount of drug required to reach effective dose may be reduced by 
development of an intermittent nebulizer or reservoir so drug is nebulized only during 
inhalation.   
There is currently a moderate amount of variability between peak drug 
concentrations detected between subjects.  However, this variability is within normal 
limits, and it is expected that increasing the number of subjects will decrease variability 
in peak drug concentrations.  A large variability in peak concentration would suggest 
unpredictable drug absorption, making dose estimation difficult.   
This study shows that remifentanil delivered by inhalation to intubated pigs is 
rapidly absorbed and rapidly cleared, consistent with earlier research on inhaled 




























remifentanil in pigs.  A larger sample size will allow for estimation of variability among 
subjects and further validate our pharmacokinetic model. 
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DETERMINATION OF REMIFENTANIL AND 
 









Remifentanil is an ester-based μ-receptor opioid agonist used for analgesia. 
Remimazolam is an ester-based benzodiazepine, which is an allosteric modulator on the 
GABAA receptor and is currently in stage III clinical trials as a new sedative agent. A 
sensitive and selective liquid-chromatography-tandem mass spectrometry (LC-MS-MS) 
method for the analysis of remifentanil and remimazolam in blood has been developed.  
This method uses a one step liquid-liquid extraction. Calibration curves of 0.25-2500 
ng/mL of both remifentanil and remimazolam were constructed by plotting concentration 
versus peak area ratio (analyte/internal standard) and fitting the data with a weighted 
quadratic equation. The accuracy of the assay ranged from 83-139% for all analytes.  The 
intra-assay precision (%RSD) for remifentanil ranged from 2.3-12.5% and from 1.7-
18.8% for remimazolam.  The interassay precision (%RSD) for remifentanil ranged from 








Remifentanil is an FDA-approved potent opioid μ agonist frequently used for 
analgesic purposes in the operative setting.  Remimazolam is a new allosteric modulator 
benzodiazepine on GABAA receptors that is currently in phase III clinical trials.  Both 
ester-based drugs are rapidly cleared by plasma esterases to metabolites with less than 
1% potency of the parent compound, and are thereby considered inactive metabolites.  
This rapid metabolism is relatively independent of hepatic and renal function and 
infusion duration,1-4 allowing for rapid recovery from the analgesic and sedative effects 
of these drugs.  The purpose of this research was to develop a sensitive and selective 
method for the co-analysis of remifentanil and remimazolam in bovine blood for future 
evaluation of co-administration of these drugs by inhalation in animals.   
 Opioids and benzodiazepines are commonly given together for anesthetic 
purposes during procedures requiring sedation.  Prior research has shown that inhaled 
remimazolam can significantly potentiate the analgesic effect of inhaled remifentanil 
when concurrently delivered (unpublished).  A method for co-analysis of inhaled 
remifentanil and inhaled remimazolam has not been previously described. 
Methods/Materials 
Drugs and Reagents 
Remifentanil was purchased from Mylan Inc (Canonsburg, PA, USA).  
Remimazolam was provided by PAION pharmaceuticals (Aachen, Germany). 
Meperidine was purchased from Sigma-Aldrich (St. Louis, MO, USA).  Formic Acid, 
acetonitrile (ACN), and methanol were purchased from Fisher Scientific (Fair Lawn, NJ, 





Bovine blood containing sodium citrate was purchased from Sierra Medical (Whittier, 
CA, USA).   
Instrumentation 
LC-MS-MS measurements were performed using a Thermo Finnigan TSQ 
Quantum AM (Thermo Scientific, Waltham, MA, USA).  Separation of remifentanil, 
remimazolam, and IS was achieved chromatographically using an Xbridge C8 (50 mm x 
2.1 mm) HPLC column (Waters, Milford, MA, USA).  The column was equilibrated at a 
flow rate of 0.25 mL/min with a mobile phase consisting of 11% ACN, 89% aqueous 
formic acid (0.1% v/v).  Upon sample injection, the concentration of ACN was increased 
at a constant rate to 30% over 4 minutes and held there for 0.5 minutes before further 
increasing to 95% ACN over 0.1 minutes and holding for 0.5 minutes, then reduced back 
to 11% ACN over 0.1 minutes and holding for 5 minutes. Flow rate remained constant at 
0.25 mL/min. The autosampler was maintained at room temperature and the injection 
volume was 20 μL.  
Calibrator and Quality Control Solution Preparation 
Stock solutions of remifentanil were prepared in saline at a concentration of 1000 
ng/μL. Stock solutions of remimazolam were prepared in a methanol solution at a 
concentration of 1000 ng/μL. Stock solutions of meperidine (IS) were also prepared at a 
concentration of 1000 ng/μL. Intermediate solutions of remifentanil and remimazolam 
were prepared at concentrations of 100, 10, 1, 0.1, and 0.01 ng/μL by performing serial 
dilutions. Intermediate solutions of IS were prepared by serial dilution to concentrations 





at -20°C for the duration of the study. Working solutions were prepared immediately 
prior to use. 
Calibrator and quality control (QC) solutions were prepared from intermediate 
solutions by aliquoting 0.5 mL of bovine blood into 13 x 100 mm screw top glass culture 
tubes (Fisher Scientific, Fair Lawn, NJ, USA) fortified with 50 ng/mL IS (25 μL of 2 
ng/μL IS). A total of 14 bovine samples were used for calibration curves with a final 
concentration of both remifentanil and remimazolam of 0, 0.25, 0.5, 1, 2.5, 5, 10, 25, 50, 
100, 250, 500, 1000, and 2500 ng/mL with a total of 50 ng/mL IS added. Liquid-liquid 
extraction was performed by adding 3 mL of ethyl acetate to each sample, vigorously 
shaking, then vortexing for 10 seconds. Samples were then centrifuged in a Beckman 
GPR centrifuge with a 20.4 cm rotor (GH 3.7) at 3,500 rpm for 10 minutes. The bottom 
organic supernatant was transferred into a new glass tube, and dried under a constant 
flow of air.  The dried residue was reconstituted in 50 μL of 20%ACN/80% H2O.  
Reconstituted samples were transferred to the autosampler for analysis.  QC samples of 
remifentanil and remimazolam were prepared in the same manner in the following 
concentrations: 500, 50, 10, and 1 ng/mL.   
Accuracy and Precision 
The accuracy of this assay was determined as the percentage of the target analyte 
concentration using the mean (n=3) assayed concentration in a single batch of samples.  
Intra-assay precision was expressed as a percent relative standard deviation (%RSD) and 
was calculated for each batch using the standard deviation of the assayed concentrations 
of each analyte at concentrations of 500, 50, 10, and 1 ng/mL divided by the mean 





the standard deviation of the assayed concentration (500, 50, 10, and 1 ng/mL, n=12) for 
three separate replicated batches by the mean concentration (n=12).   
Recovery 
The recovery of remifentanil and remimazolam from bovine blood was 
determined using quality control samples (n=3) at 500 and 10 ng/mL.  Recovery was 
assessed by comparing the concentrations obtained for quality control samples processed 
as described to samples that were extracted and the internal standard added immediately 
prior to evaporation of solvent.  The ratio of the two concentrations represented the 
percentage of analyte recovered by the extraction.   
Stability 
The effect of various storage conditions on sample stability was determined for 
each analyte using quality control samples.  Quality control samples (n=3) at 500, 50, 10, 
and 1 ng/mL were stored at room temperature in the auto sampler overnight, and were re-
run against freshly prepared calibrators and controls.  There was no degradation of 
internal standard under these conditions.  Concentrations of 500 and 10 ng/mL were 
stored for 1 hour in blood at room temperature on the bench top prior to extraction, and 
were compared to samples immediately extracted.  Samples were analyzed as described.  
Stability was assessed by comparing the mean assayed concentration (n=3) for the 









The analysis of remifentanil and remimazolam in blood by LC-MS-MS exhibited 
a lower limit of detection (LLOD) of 0.25 ng/mL and a lower limit of quantification 
(LLOQ) of 1 ng/mL. The upper limit of quantification (ULOQ) was 2500 ng/mL for both 
drugs. Remifentanil was readily detectable at 3.26 minutes with a run time of 10.3 
minutes.  The predominant product ion had a mass to charge ratio of 285 (m/z 
377.1→285.0).  Remimazolam was readily detectable at 4.81 minutes with the 
predominant product ion having a mass to charge ratio of 406 (m/z 439.0→406.8). 
Meperidine (IS) was readily detectable at 3.3 minutes with a predominant product having 




Figure 5.1. Structures of meperidine (IS), remifentanil, and metabolites GI-90291 







Figure 5.2. A. Chromatogram of remifentanil, meperidine, and  
remimazolam at a concentration of 50 ng/mL (left) 
B.  Chromatogram of a blank sample of 
remifentanil and remimazolam at 0 
ng/mL, meperidine concentration 
of 50 ng/mL (right). 
 
The plot of the ratio of analyte and internal standard peak areas versus calibrator 
concentration was nonlinear over the range of 0.5-2500 mg/mL. 
Calibration curves were fit to a quadratic equation, weighted 1/Y2, where Y was 
the analyte/IS.  Calibration curves generated in this manner exhibited a correlation 
coefficient (r2) that was typically ≥0.98.  The accuracy of the LC-MS-MS assay was 
>79% (n=3). 
Intra-assay precision was ≤12% for remifentanil and ≤15% for remimazolam for 
all quality control concentrations. 





for all quality control concentrations (Table 5.1). Recovery of remifentanil from blood 
was between 89-103%, recovery of remimazolam from blood was 79-104% (Table 5.2).  
Samples were recovered at 67-74% for remifentanil after 36 hours in the auto-sampler at 
room temperature, while remimazolam was recovered at 102-118%.  Samples left at 
room temperature on the bench top for 1 hour were recovered at 66% for remifentanil and 
58-68% for remimazolam (Table 5.3). 
   
Table 5.1.  Accuracy and Intra- and Interassay Precision (%RSD) for Quality 
Control Standards Containing Remifentanil and Remimazolam 
 Remifentanil Remimazolam 











































































Table 5.3.  Stability of Remifentanil and Remimazolam in Standards 
Stored Under Various Conditions 










74 ± 11 
71 ± 4 
77 ± 2 
67 ± 11 
 
118 ± 56 
108 ± 2 
102 ± 12 
108 ± 2 




66 ± 7 
66 ± 9 
 
58 ± 11 






We developed a method for the detection of remifentanil and remimazolam in 
blood using LC-MS-MS. Using this method, the assayed concentrations for the fortified 
quality control samples were 88-119% for remifentanil and 83-139% of the target 
concentration for remimazolam.   
For quality controls, remimazolam showed more variability than remifentanil, 
especially at the very low concentrations (1 ng/mL).  This may be due to some carry-over 
on the LC-MS-MS for remimazolam.  The lowest concentration for remimazolam may 
need to be increased to 2.5 ng/mL. Also, larger sample sizes may be necessary.  Level of 
detection is lower than therapeutic doses, allowing for detection of recovery from each 
drug.  
When stored at room temperature in the autosampler, remifentanil showed 
expected degradation, but there was an increase in concentration for all remimazolam 
samples.  This may also due to carry-over in the LC-MS-MS.  The expected degradation 
was seen when blood was left for 1 hour on the bench top in blood.   
Further refinement of this method for detection of remifentanil and remimazolam 
in combination will be necessary for pharmacokinetic sampling of remimazolam and 
remifentanil in animals. 
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 Throughout this dissertation, the feasibility, efficacy, and safety of delivering the 
ultra-short acting analgesic agent remifentanil and the sedative agent remimazolam by 
inhalation has been evaluated.  It was our hypothesis that inhaled remifentanil and 
remimazolam would be rapidly absorbed, pharmacologically active, rapidly cleared, and 
noninjurious to airways in rodent models.  Following positive rodent findings, we 
continued this research in a porcine model.   
Our conclusions were that inhaled remifentanil was rapidly absorbed, with onset 
of action within 2 minutes; it was also pharmacologically active, with detectable blood 
level and evidence of profound analgesic effect when measured with a tail flick meter.  
Inhaled remifentanil was also rapidly cleared, with recovery within 3 minutes.  
Additionally, there was no evidence of inflammation or irritation to rodent airways, and 
tissues were histologically normal.   
Our research on inhaled remimazolam in rodents found that there was no apparent 
sedative effect in rats, most likely attributable to dosing limitations.  There was, however, 
marked sedative effect in mice as evidenced by time to movement outside a perimeter.  
Follow-up research showed that low dose inhaled remimazolam potentiated the analgesic 





remimazolam in rat blood following pulmonary exposure, and there was no evidence of 
lung irritation in mice when the drugs were combined.   
Preliminary research on inhaled remifentanil in pigs shows rapid uptake and rapid 
metabolism, with a population half-life of 3 minutes, which is similar to the half-life of 
intravenous remifentanil. We have established that these drugs are rapidly absorbed and 
highly efficacious, while being nonirritating to the lungs.  While moving forward with 
our large animal model in pigs, we are also looking forward to testing these medications 
in a humans.   
 There is debate regarding the future of inhalational anesthesia.1,2  Currently, 
volatile anesthetics are used for most general anesthetics, with inhaled nitrous oxide 
being used for both general and sometimes sedation anesthesia. The first general 
anesthetics ever delivered were inhaled anesthetics, starting with diethyl ether in 1846.3 
Modern inhaled anesthetics are halogenated with fluorine, thereby limiting metabolism 
and thus toxicity. However, rate of inhaled anesthetic onset and offset still depend upon 
their solubility and vapor pressure.  Volatile anesthetics are minimally soluble in the 
blood, allowing for rapid induction and emergence, and are minimally metabolized (0.02-
5%), limiting toxicity to the liver and kidneys.3,4  Additionally, surrogate measures of 
effect site concentration can be inferred from the pulmonary percentage or partial 
pressure of these gases.4,5  However, the use of inhaled anesthetics is falling out of favor 
with some anesthesia providers.  
Volatile anesthetics and nitrous oxide have a tendency to be emetogenic.  They 
are also very resistant to biologic degradation and thus deactivation, which can result in 





anesthetic.  This can present a safety risk in patients such as those with obstructive sleep 
apnea.  This is especially true if the patient has been significantly dosed with 
supplemental opioids during the case.  Additionally, another drawback of nitrous oxide 
and volatile anesthetics, which are chlorofluorocarbons, is that they are all greenhouse 
gases.6 
Total intravenous anesthetics (TIVA) has become increasingly popular due to the 
development of an ultra-short acting class of intravenous anesthetics, or “soft drugs”, 
such as remifentanil, as well as improved hypnotics with attenuated side effects, such as 
propofol. These drugs afford the anesthesia provider a new level of control, with rapid 
intravenous inductions and rapid emergence, increasing safety, facilitating shorter turn 
around times, and increasing the efficiency of the operating room.7,8   
However, TIVA has its own limitations.  Direct access to the circulation is 
required for IV anesthetics.  This type of anesthesia is vulnerable to drug dilution and 
dosing errors as well as contamination. It lacks the surrogate effect site concentration 
measurement that the volatile anesthetics and nitrous oxide allow.  It is also more 
complex to setup.   
This research shows that all the pharmacokinetic benefits of these “soft drugs”, as 
shown during intravenous administration, are maintained during the easier administration 
technique of inhalation. To reiterate, these pharmacokinetic benefits include liver and 
kidney independent metabolism and a short context-sensitive half-life9,10  These benefits 






 Intravenous medication dosing for sedation or general anesthesia is inconvenient 
for patients and providers.  Although necessary for safety, establishing intravenous access 
is painful for the patient and at times, time consuming for the practitioner.  This is 
especially true for very minor procedures such as skin tag removal and/or cataract 
surgery.  In order for drugs to be infused, some require dilution and a majority, if not all, 
are delivered based on weight.  Additionally, multiple IV pumps with separate 
programming are required when multiple medications are infused.  Sometimes, certain 
combinations of medications cannot be administered in one carrier line due to precipitate 
formation or other incompatibility issues.  Over-dosage of intravenous medications for 
sedation, whether by infusion or boluses, is frequent and results in respiratory or 
hemodynamic depression. This generally will require life-sustaining measures by the 
practitioner.  Of course, this is balanced against under-sedation in which the patient is 
anxious or in pain.  
We envision a respiratory-dosed, multimodal and thus balanced anesthetic for 
maintenance of general anesthesia.  A short acting, inhaled benzodiazepine dynamically 
mixed with a short acting inhaled opioid would be the amnestic/analgesic combination to 
accommodate extremes of patient age, weight, and comorbidities. Kinetically, taking into 
account the potentiating effects of benzodiazepines and opioids, combinations to produce 
general anesthetic maintenance could be dynamically calculated and altered based on 
needs due to age, cardiac comorbidities, and tolerance.  Opioid tolerant patients may 
require more longer-acting opioids (fentanyl, sufentanil, morphine, or hydromorphone) to 
be titrated instead of the shorter acting opioid.  These opioids could also be administered 





anesthesia is clinically superior to the current inhaled anesthetics because of rapid 
esterase metabolism of both drugs and the ability to selectively reverse either drug when 
a patient fails to adequately emerge from general anesthesia.  Currently, when patients 
are slow to emerge from general anesthesia, there is not a competitive reversal agent for 
volatile anesthetics.  Thus, sadly, the clinician may try to reverse the synergist aspect of 
the opioid.  This can leave a patient in significant postoperative pain.  
Currently, intravenous dosing of amnestics and analgesics for sedation is even 
more complex because of the complex balance between adequate sedation and 
maintaining spontaneous respiration during rapidly changing surgical stimuli.  Sedation 
level is targeted by arbitrary intravenous infusions and/or bolus dosing.  Also, unlike 
most general anesthetics, sedation does not have a secure or semisecure airway.  
Handling apnea requires in-depth knowledge and an advanced airway skill sets. 
Respiratory dosing of these same medications for sedation has the advantage of patient- 
controlled dosing during the procedure.  When the surgical stimulus becomes intense, the 
patients’ minute ventilation will increase, thereby self-dosing more medication.  When 
the medications cause more sedation and/or the surgical stimulus abates, the patients’ 
minute ventilation will decrease, thereby decreasing self-dosing.  The inherent safety 
mechanism is that these specific medications are esters and are broken down by the non-
specific esterases in the patients’ blood.  This will help prevent dangerous, apnea-
producing levels in the patients’ blood.  Further studies could help elucidate if, when a 
patient is breathing oxygen with these medications, if they will be adequately sedated but 
can self-rescue themselves before oxygenation desaturation or hypoxia occurs.  





reverse either the opioid or benzodiazepine.  Further, since these medications are not 
volatiles, scavenging these medications may be less complex in the office-based 
environment. 
The practice of anesthesiology has become more challenging.  Adequate care of 
patients is threatened by drug shortages and complicated by rules as put forth by USP 
797.  So even though drug shortages are prevalent, USP 797 states that unless drugs are 
drawn in aseptic conditions in the pharmacy, syringe drawn drugs must be administered 
within an hour.   This can have an impact on the efficiency and cost of anesthetic 
administration.  New controlled and regulated systems in which these drugs could be 
administered via inhalation could help. 
 Development of these drugs and delivery devices will require collaboration 
between many disciplines, including pharmacology, bioengineering, and anesthesiology. 
With the development of any new drug or device, there are obstacles to overcome.  
Continued pig testing and human testing must evaluate for intersubject variability.  Large 
variability between subjects would make it difficult to estimate required dose. Currently, 
during general anesthesia, gas analyzers test the percentage of drug in a patient’s exhaled 
breath to estimate depth of anesthesia when volatile anesthetics are used. However, these 
drugs are not metabolized and are essentially ideal gases that are governed by the ideal 
gas law and rules of partial pressure and solubility. An alternative system would need to 
be developed to assess depth of anesthesia for inhaled opioids and benzodiazepines.  
 Another hurdle to overcome will be potential for abuse.  A noninvasively 
delivered opioid and benzodiazepine would have significant abuse potential. Ways would 





anesthesia machine could eliminate the need to reconstitute, and could prevent drug 
waste by preventing contamination caused by intravenous use, there would also be the 
added expense of altering the configuration of the anesthesia machine to accommodate, 
deliver, and monitor drug cartridges.   
 Testing would still have to be ongoing with respect to tolerability of the drugs.  
Human testing would still need to occur.  Investigation would have to occur with regard 
to allergies.  Patients can have more allergies to esters.  Also, a question of how the drug 
tastes when administered to awake humans will also have to be investigated.  
Drug deposition variability would have to be studied for both general anesthetic 
and sedated patients.  There would be obvious differences in deposition during positive 
pressure ventilation and spontaneous ventilation.  Differences in deposition differences 
between males and females and extremes of age would have to be studied.  Many 
comorbid conditions would also have to be studied.  A few would include COPD, 
restrictive lung disease, and pulmonary hypertension. 
 Use of inhaled ester-based drugs presents a paradigm shift for anesthesia.  These 
drugs are metabolized at a constant rate by plasma esterases independent of kidney and 
liver metabolism, are fully reversible by intravenous injection, and therefore present a 
safer option for extremes in age, the morbidly obese, and patients with multiple co-
morbid conditions whether they are delivered by IV or by inhalation.  The added benefit 
of inhalation delivery is a noninvasive delivery method and dynamic respiratory dosing 
which has an increased margin of safety. Throughout this dissertation, we have shown 
that inhalation of these drugs is feasible.  It is our hope that future research in this area 
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AEROSOL PARTICLE SIZE AND DEPOSITION 
 
 
Useful information on factors affecting the choices of nebulizers and aerosol deposition 
in the lungs:  
1. Particle size 
2. Mode of inhalation: speed, volume, frequency, breath holding 
3. Anatomy and morphology: variation and disease states 
• Peak alveolar deposition occur with diameter of 2-4 microns 
• Slow lung inhalation (30L/min) enhances both lung deposition and clinical effect 
of inhaled drugs 
 
Jet Ventilators:  
 
Work on Bernoulli principle. As kinetic energy of the air increases, its potential 
energy and pressure falls, allowing liquid from the nebulizer reservoid to be pulled up 
and released as droplets. These droplets range from 1-100 microns.  Larger droplets are 
not released, and run back into the reservoir, and are recycled. It takes several minutes to 
nebulize a dose of drug contained in 2-5 mL, a minimum of 2 mL is required, most of the 




Contain synthetic ceramic piezoelectric crystal, usually vibrating at 1-3 MHz in 





nebulized fluid, forming a fountain above the crystal. Small droplets leave the nebulizer 
by being entrained in patient’s airflow. Ultrasonic nebulizers are smaller and quieter than 
jet ventilators, and have higher output rates, leading to shorter nebulization times.  
However, they do tend to have slightly larger droplet size.  Ultrasonic nebulizers have 
difficulty aerosolizing viscous solutions.   
 
Vibrating Mesh Nebulizers:  
 
Use ultrasonics to generate the aerosol, but have a different principle of operation.  
The mesh is stainless steel and has holes drilled by a laser drilling process. The mesh 
vibrates around 100 kHz, which causes liquid to be ejected from the holds forming 
droplets of relatively uniform size.  There is no need to eliminate large droplets. The 
residual volume is much smaller, and volumes as small as 1 mL can be nebulized.  
Aeroneb (a vibrating mesh nebulizer) has up to 1,000 holes.  This nebulizer reduces 
waste, decreases nebulization times, and improves convenience. 
 
Deep Lung Deposition: 
Highest in compliant, ambulating patients who can take slow deep breaths 
through a mouthpiece (to minimize nasal deposition). However, mechanically ventilated 
patients can benefit from choice of nebulizer, placement of nebulizer in the circuit, and 
adjustment of ventilator settings to increase inspiratory times so that deposition can be 
almost the same as ambulatory patients. 
 
Source: Newman S. Respiratory Drug Delivery: Essential Theory and Practice.  
Richmond, VA: Respiratory Drug Delivery Online; 2009. 
 
